Firm expects to begin Phase I testing by early 2009.
PCAS Pharma Synthesis will manufacture the first batch of Quantum Genomics’ (QGC) preclinical candidate for hypertension. QGC expects to start the first clinical trial of this drug by early 2009.
QCC001 exploits a new biological mechanism with the potential to control of blood pressure, according to QGC.
Besides producing QCC001, PCAS will also conduct stability studies. QGC expects an initial cGMP batch of several kilograms.
